CAR-2219

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug NameCAR-2219
Drug Alias NameCAR2219CAR-2219CAR2019CAR-2019CAR19 +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMultiple MyelomaLymphoma, T-CellLymphoma, B-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, T-CellLymphoma, B-Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A